Benitec Biopharma (NASDAQ:BNTC) Lifted to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Benitec Biopharma (NASDAQ:BNTC) to a strong-buy rating in a research report sent to investors on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($5.45) EPS, FY2025 earnings at ($1.81) EPS and FY2026 earnings at ($1.83) EPS.

A number of other equities analysts have also recently issued reports on BNTC. SVB Leerink initiated coverage on shares of Benitec Biopharma in a research report on Monday. They set an outperform rating and a $13.00 target price for the company. Piper Sandler assumed coverage on Benitec Biopharma in a research note on Thursday, June 13th. They issued an overweight rating and a $30.00 target price on the stock. Finally, JMP Securities increased their target price on Benitec Biopharma from $10.00 to $16.00 and gave the company a market outperform rating in a report on Monday, April 22nd.

Benitec Biopharma Trading Up 3.1 %

BNTC opened at $9.27 on Monday. The stock’s 50 day simple moving average is $8.37 and its 200 day simple moving average is $6.14. Benitec Biopharma has a 1-year low of $1.86 and a 1-year high of $10.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.18 and a current ratio of 4.18.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share for the quarter. On average, sell-side analysts anticipate that Benitec Biopharma will post -7.67 earnings per share for the current year.

Institutional Investors Weigh In On Benitec Biopharma

An institutional investor recently raised its position in Benitec Biopharma stock. GAMMA Investing LLC increased its position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) by 53.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,438 shares of the biotechnology company’s stock after acquiring an additional 1,884 shares during the quarter. GAMMA Investing LLC owned approximately 0.06% of Benitec Biopharma worth $38,000 as of its most recent filing with the SEC. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.